Literature DB >> 11818206

A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors.

N S Andersen1, M K Jensen, P de Nully Brown, C H Geisler.   

Abstract

This study presents the first large clinical analysis of 105 unselected mantle cell lymphoma (MCL) patients diagnosed from 1992 to 2000 in a well-defined Danish population. The annual incidences were 0.7/100000 for men and 0.2/100000 for women, with no significant change during the study period. Of 97 evaluable cases, 43% achieved a complete response (CR) after initial therapy. The median disease-free (DFS) and overall survival (OS) rates were 15 and 30 months, respectively. In multivariate analysis, splenomegaly (P=0.002), anaemia (P=0.0001) and age (P=0.002), but not the international prognostic index (IPI) and the Ann Arbor staging system, had an independent impact on survival. Moreover, in a sub-analysis of 45 younger MCL patients (<65 years), a trend towards an OS plateau of 58% was observed in cases without splenomegaly and anaemia (n=29). Thus, in contrast to previously suggested prognostic factors, these variables may prove useful for clinical decisions in a significant subset of MCL patients.

Entities:  

Mesh:

Year:  2002        PMID: 11818206     DOI: 10.1016/s0959-8049(01)00366-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

1.  Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Authors:  Rekha Rao; Srilatha Nalluri; Warren Fiskus; Andrew Savoie; Kathleen M Buckley; Kyungsoo Ha; Ramesh Balusu; Atul Joshi; Veena Coothankandaswamy; Jianguo Tao; Eduardo Sotomayor; Peter Atadja; Kapil N Bhalla
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

2.  Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.

Authors:  Matthew A De Niear; John P Greer; Adam Seegmiller; Louise A Mawn
Journal:  Ocul Oncol Pathol       Date:  2018-11-16

3.  Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Authors:  Caroline Bodet-Milin; Cyrille Touzeau; Christophe Leux; Mehmet Sahin; Anne Moreau; Hervé Maisonneuve; Nadine Morineau; Henry Jardel; Philippe Moreau; Céline Gallazini-Crépin; Pascal Gries; Rémy Gressin; Jean-Luc Harousseau; Mohamad Mohty; Philippe Moreau; Françoise Kraeber-Bodere; Steven Le Gouill
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-29       Impact factor: 9.236

4.  Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Authors:  Warren Fiskus; Rekha Rao; Ramesh Balusu; Siddhartha Ganguly; Jianguo Tao; Eduardo Sotomayor; Uma Mudunuru; Jacqueline E Smith; Stacey L Hembruff; Peter Atadja; Victor E Marquez; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

5.  Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.

Authors:  Saskia A M van de Schans; Maryska L G Janssen-Heijnen; Marten R Nijziel; Ewout W Steyerberg; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

6.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

7.  The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?

Authors:  S Y Lim; J M Horsman; B W Hancock
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

8.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

9.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Authors:  Lloyd E Damon; Jeffrey L Johnson; Donna Niedzwiecki; Bruce D Cheson; David D Hurd; Nancy L Bartlett; Ann S Lacasce; Kristie A Blum; John C Byrd; Michael Kelly; Wendy Stock; Charles A Linker; George P Canellos
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Authors:  R Schaffel; C V Hedvat; J Teruya-Feldstein; D Persky; J Maragulia; D Lin; C S Portlock; C H Moskowitz; A D Zelenetz
Journal:  Ann Oncol       Date:  2010-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.